We are live on ! Find out more
RXII

GALENA BIOPHARMA INC COM
RXII

Delisted

RXII was delisted on the 25th of October, 2011.

Back to rankings

85 hedge funds and large institutions have $44.3M invested in GALENA BIOPHARMA INC COM in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 27 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more call options, than puts

Call options by funds: $5.8M | Put options by funds: $4.94M

6% less funds holding

Funds holding: 90 → 85 (-5)

11% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 27

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

36% less capital invested

Capital invested by funds: $68.9M → $44.3M (-$24.7M)

Holders
85
Holders Change
-5
Holders Change %
-5.56%
% of All Funds
2.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
24
Reduced
27
Closed
17
Calls
$5.8M
Puts
$4.94M
Net Calls
+$857K
Net Calls Change
+$398K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$305K
2
BIT
BlackRock Institutional Trust
California
+$267K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$258K
4
Group One Trading
Group One Trading
Illinois
+$248K
5
State Street
State Street
Massachusetts
+$172K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$1.65M
2
Invesco
Invesco
Georgia
-$1.18M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$468K
4
BFA
BlackRock Fund Advisors
California
-$242K
5
LPL Financial
LPL Financial
California
-$155K
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
51
Parametric Portfolio Associates
Washington
$48K +$48K +23,106 New
TRCT
52
Tower Research Capital (TRC)
New York
$45K +$45K +21,897 New
Barclays
53
Barclays
United Kingdom
$38K -$14.6K -7,444 -28%
Nomura Holdings
54
Nomura Holdings
Japan
$37K -$1.97K -930 -5%
JG
55
Jefferies Group
New York
$35K +$35K +16,930 New
CI
56
Cowen Inc
New York
$35K +$35K +17,200 New
Cambridge Investment Research Advisors
57
Cambridge Investment Research Advisors
Iowa
$33K +$33K +15,819 New
Commonwealth Equity Services
58
Commonwealth Equity Services
Massachusetts
$32K – – –
CCM
59
Compton Capital Management
Rhode Island
$31K – – –
Citigroup
60
Citigroup
New York
$29K -$21.4K -10,672 -43%
SFSIG
61
San Francisco Sentry Investment Group
California
$28K +$13K +6,200 +87%
M&T Bank
62
M&T Bank
New York
$28K +$28K +13,510 New
CCM
63
Chickasaw Capital Management
Tennessee
$26K – – –
VFS
64
VSR Financial Services
Kansas
$25K +$25K +12,297 New
AB
65
Amalgamated Bank
New York
$24K -$19 -9 -0.1%
BCM
66
Buckhead Capital Management
Georgia
$24K +$24K +11,630 New
Prudential Financial
67
Prudential Financial
New Jersey
$22K -$23.6K -11,700 -52%
Creative Planning
68
Creative Planning
Kansas
$22K -$147 -70 -0.7%
AG
69
Aperio Group
California
$21K -$2.32K -1,119 -10%
PAM
70
Princeton Alpha Management
New Jersey
$21K +$21K +10,069 New
William Blair & Company
71
William Blair & Company
Illinois
$20K – – –
Bessemer Group
72
Bessemer Group
New Jersey
$19K – – –
Deutsche Bank
73
Deutsche Bank
Germany
$12K -$81.9K -41,849 -87%
NFG
74
Next Financial Group
Texas
$9K +$9K +4,500 New
Canada Life
75
Canada Life
Manitoba, Canada
$8K +$884 +410 +12%
1 2
3
4 5

RXII Hedge Fund Activity: Q3 2014 in Review

85 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q3 2014, worth a combined $44.3M — down 36% from $68.9M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RXII and 14 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 24 added.

The largest buyer was Morgan Stanley, adding an estimated $305K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $1.65M sold.

  • 85 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q3 2014, down from 90 in Q2 2014.
  • Funds reported $44.3M of GALENA BIOPHARMA INC COM stock for Q3 2014, down 36% quarter-over-quarter.
  • 14 funds opened new GALENA BIOPHARMA INC COM positions in Q3 2014 and 17 closed out, a net change of -3 holders.
  • The largest GALENA BIOPHARMA INC COM buyer in Q3 2014 was Morgan Stanley, an estimated $305K added.
  • The largest GALENA BIOPHARMA INC COM seller in Q3 2014 was Bridgeway Capital Management, an estimated $1.65M sold.

Based on aggregated 13F filings for Q3 2014.